Display options
Cite
Lloyd-Jones JG, Henson R, Nichols JD, et al. Pharmacokinetics of intravenous and oral tolmesoxide. Eur J Clin Pharmacol. 1981;19(2):119-25doi: 10.1007/BF00568398.
Lloyd-Jones, J. G., Henson, R., Nichols, J. D., Greenslade, D., & Clifford, J. M. (1981). Pharmacokinetics of intravenous and oral tolmesoxide. European journal of clinical pharmacology, 19(2), 119-25. https://doi.org/10.1007/BF00568398
Lloyd-Jones, J G, et al. "Pharmacokinetics of intravenous and oral tolmesoxide." European journal of clinical pharmacology vol. 19,2 (1981): 119-25. doi: https://doi.org/10.1007/BF00568398
Lloyd-Jones JG, Henson R, Nichols JD, Greenslade D, Clifford JM. Pharmacokinetics of intravenous and oral tolmesoxide. Eur J Clin Pharmacol. 1981 Jan;19(2):119-25. doi: 10.1007/BF00568398. PMID: 7202471.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Eur J Clin Pharmacol. 1981 Jan;19(2):119-25. doi: 10.1007/BF00568398.

Pharmacokinetics of intravenous and oral tolmesoxide.

European journal of clinical pharmacology

J G Lloyd-Jones, R Henson, J D Nichols, D Greenslade, J M Clifford

PMID: 7202471 DOI: 10.1007/BF00568398

Abstract

A high pressure liquid chromatographic assay was developed for simultaneous measurement of the plasma levels of tolmesoxide and its principal metabolite, RX71112. The assay was used to study the disposition of intravenous and oral tolmesoxide in ten normotensive subjects. Two exponential terms were required to describe the disposition of the drug following intravenous administration, whilst a single exponential term sufficed to account for the decay in the plasma concentration after oral administration. The bioavailability of oral tolmesoxide from capsules averaged 84.5% and was independent of dose. The mean half-life after i.v. dosing was 2.6 h (+/- 0.3 SEM) compared to values of 1.9 h (+/- 0.1 SEM) and 2.7 h (+/- 0.5 SEM) following 200 and 400 mg oral doses respectively. In all subjects RX71112 appeared in plasma shortly after tolmesoxide following both routes of administration. The terminal half-life of the metabolite was significantly longer than tolmesoxide with a mean value of 4.9 h (+/- 0.9 SEM) following the 200 mg oral dose of tolmesoxide. The binding of tolmesoxide and RX71112 at therapeutic plasma concentration was 36.8% (+/- 0.5 SEM) and 58.5% (+/- 0.3 SEM) and this remained unchanged at higher concentrations.

References

  1. Clin Pharmacol Ther. 1980 Jan;27(1):76-82 - PubMed
  2. Br J Pharmacol. 1978 May;63(1):111-8 - PubMed
  3. Clin Pharmacol Ther. 1975 Oct;18(4):377-90 - PubMed
  4. Br J Clin Pharmacol. 1978 Jan;5(1):35-44 - PubMed
  5. J Pharm Sci. 1970 Jan;59(1):53-5 - PubMed
  6. Xenobiotica. 1981 Feb;11(2):89-96 - PubMed
  7. Br J Clin Pharmacol. 1979 Oct;8(4):402P - PubMed
  8. Eur J Clin Pharmacol. 1981 Jan;19(2):113-8 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources